WCLC 2025 - Posters & ePosters-EP.05.01 Use of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Molecular Characterization of Non-Small Cell Lung Cancer

EP.05.01 Use of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Molecular Characterization of Non-Small Cell Lung Cancer

Back to course

Pdf Summary

This study evaluates the use of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in the molecular characterization of non-small cell lung cancer (NSCLC). EBUS-TBNA is the gold-standard technique for sampling hilar and mediastinal lesions. Molecular profiling in NSCLC aims to detect genetic and molecular alterations that impact tumor development, progression, and response to therapy.<br /><br />A retrospective cohort study was performed at Hospital Clínic de Barcelona, analyzing 836 patients undergoing linear EBUS between 2021 and 2024. From these, 147 NSCLC patients who had EBUS-TBNA for molecular testing were included.<br /><br />Results showed that 83% of EBUS-TBNA samples provided adequate material for molecular analysis, with 16% negative and 1% not performed. Common detected mutations included KRAS (27%), EGFR (13%), TP53 (17%), and others such as MET, RET, BRAF, and ALK. For PD-L1 expression analysis, 82% of samples were adequate, with 39% testing positive, 43% negative, and 18% not performed.<br /><br />The findings demonstrate that cytological specimens obtained via EBUS-TBNA are highly suitable for comprehensive molecular profiling of NSCLC. This supports their critical role in enabling precision oncology approaches and facilitating personalized targeted therapies. The study underlines the importance of EBUS-TBNA as a minimally invasive, reliable method to obtain tissue for genetic and immunologic biomarkers essential for guiding treatment decisions in NSCLC patients.

Asset Subtitle

Estrella Caballeria Lamelas

Meta Tag

Speaker Estrella Caballeria Lamelas

Topic Pulmonology and Staging

Keywords

EBUS-TBNA

non-small cell lung cancer

NSCLC

molecular profiling

genetic mutations

KRAS

EGFR

PD-L1 expression

precision oncology

targeted therapies